Editorial: Management of bladder cancer

Journal of Urology

Volumn 171, Issue 6 I, 2004, Pages 2482-2483

  Lamm, Donald L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ALPHA3B INTERFERON; ANTISENSE OLIGODEOXYNUCLEOTIDE; BCG VACCINE; CLUSTERIN; DIMETHYL SULFOXIDE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; MEGLUMINE GAMMA LINOLEIC ACID; MITOMYCIN C; ONCOVITE; PROGESTERONE; TAMOXIFEN; THIOTEPA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; GENETIC ENGINEERING; GROWTH INHIBITION; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; RANDOMIZATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; ANIMAL; BLADDER TUMOR; MULTIMODALITY CANCER THERAPY; NOTE;

ANIMALS; COMBINED MODALITY THERAPY; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 3042575514     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000127757.72243.3e     Document Type: Editorial

References (11)

1. Lam, J. S., Benson, M. C., O'Donnell, M. A., Sawczuk, A., Gavazzi, A., Wechsler, M. H. et al: Bacillus Calmete-Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol, 21: 354, 2003
2. Kaasinen, E., Rintala, E., Pere, A. K., Kallio, J., Puolakka, V. M., Liukkonen, T. et al: Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. J Urol, 164: 47, 2001
3. Harris, N. M., Anderson, W. R., Lwaleed, B. A., Cooper, A. J., Birch, B. R. and Solomon, L. Z.: Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma. Cancer, 97: 71, 2003
4. Lewin, J., Cooper, A. and Birch, B.: Progesterone: a novel adjunct to intravesical chemotherapy. BJU Int, 90: 736, 2002
5. Pu, Y. S., Hsieh, T. S., Cheng, A. L., Tseng, N. F., Su, J., Hsieh, C. Y. et al: Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy. Br J Urol, 77: 76, 1996
6. See, W. A. and Xia, Q.: Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. J Natl Cancer Inst, 84: 510, 1992
7. Bahnson, R. and Ratliff, T. L.: Effects of interferon in combination with cytotoxic drugs on mouse bladder tumor (MBT-2) growth in vitro and in vivo. J Urol, 140: 656, 1988
8. Kaasinen, E., Wijkstrom, H., Malmstrom, P. U., Hellsten, S., Duchek, M., Mestad, O. et al: Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol, 43: 637, 2003
9. Fukui, I., Kihara, K., Sekine, H., Tachibana, Y., Kawai, T., Ishiwata, D. et al: Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response. Cancer Chemother Pharmacol, suppl., 30: S37, 1992
10. Shelley, M. D., Court, J. B., Kynaston, H., Wilt, T. J., Coles, B. and Mason, M.: Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev, 3: CD003231, 2003
11. Sekine, H., Ohya, K., Kojima, S. I., Igarashi, K. and Fukui, I.: Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. Int J Urol, 8: 483, 2001